October 6, 2020, Vol 324, No. 13, Pages 1261-1362
Emergency Use Authorizations During the COVID-19 PandemicLessons From Hydroxychloroquine for Vaccine Authorization and Approval
Kyle Thomson, JD, MPH; Herschel Nachlis, PhD
free access has active quiz has multimedia has audio
JAMA. 2020;324(13):1282-1283. doi:10.1001/jama.2020.16253
This Viewpoint uses the FDA’s Emergency Use Authorization (EUA) of hydroxychloroquine for COVID-19 treatment to emphasize the costs of premature regulatory authorizations to public health and trust, and proposes the use of advisory committees, requirements for postmarketing surveillance, and adherence to standards of transparency for any future EUAs.